Uganda begins Phase Ib clinical trials for Bundibugyo Ebola vaccine

Uganda has officially launched Phase Ib clinical trials for a candidate vaccine targeting the Bundibugyo strain of the Ebola virus. The Africa Centres for Disease Control and Prevention (Africa CDC) confirmed that the trials for the ChAdOx1 BDBV vaccine commenced on October 6. This research milestone occurs as the region remains on high alert due to a significant Ebola outbreak in the neighbouring Democratic Republic of Congo (DRC), which has recorded more than 4,000 fatalities according to recent health reports.

The ChAdOx1 BDBV vaccine was developed by scientists at the University of Oxford. The progression to Phase Ib in Uganda follows successful Phase Ia trials previously conducted in Britain. In addition to the Oxford-developed candidate, a second vaccine developed by Moderna has received ethical approval to begin trials in Uganda. The Moderna vaccine candidate has already undergone initial testing in Canada. These developments represent a proactive effort to expand the medical toolkit against diverse strains of the virus that have historically caused devastating outbreaks in East and Central Africa.

The urgency for a Bundibugyo-specific vaccine is underscored by the ongoing health crisis in the DRC. As of October 6, the DRC has documented 8,728 confirmed cases and 4,205 deaths. While the DRC has received 70,000 doses of the Ervebo vaccine to manage the current situation, health officials note that the Ervebo vaccine is not effective against the Bundibugyo strain. Establishing the safety and efficacy of new candidates like ChAdOx1 BDBV is considered a critical step for long-term regional health security and future pandemic preparedness.